2820 - 200 Granville Street Vancouver, BC Canada V6C 1S4
phone. 604 336 7906 www.aequuspharma.ca

Aequus Reports Second Quarter 2025 Financial Highlights

VANCOUVER, August 28, 2025 – Aequus Pharmaceuticals Inc. (TSX-V: AQS) ("Aequus" or the "Company"), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, today reports financial results for the quarter ended June 30, 2025 ("Second Quarter 2025"). Unless otherwise noted, all figures are in Canadian currency.

Financial Report Highlights

Aequus reported $218,220 in revenue during Second Quarter 2025 compared to revenue of $161,413 generated during the same period in 2024 – an increase of $56,807, or 35%. During the six months ended June 30, 2025 ("YTD 2025") Aequus achieved $444,765 in revenues compared to $213,968 generated during the six months ended June 30, 2024 ("YTD 2024") – an increase of $230,797, or 108%.

Net losses decreased by 76% in the second quarter of 2025, compared to the same period in 2024, with a net loss of $163,909 in Q2 2025 versus $683,033 in Q2 2024. For the six months ended June 30, 2025, the Company reported a net loss of $809,010, representing a 39.9% reduction from the net loss of $1,345,121 for the same period in 2024. The year-to-date improvement was primarily driven by a $931,865 (62%) decrease in expenses, partially offset by an increase of $485,200 in other expenses related to the impairment of a right-of-use asset.

Highlights from the quarter are as follows:

- Sales and marketing costs during Second Quarter 2025 were $42,985 compared to $538,159 in Second Quarter 2024, a decrease of $495,174 or 92%. This decrease was mainly driven by the complete layoff of the sales and marketing team in Q4 2024.

- General and administration and interest ("G&A") expenses were $226,597 in Second Quarter of 2025 compared to $259,428 in Second Quarter of 2024, a decrease of $32,831. The changes in G&A expenses were mainly driven by general cost-cutting measures offset for higher loan-related expenses and rent expenses.

On July 22 2025, the Company entered into a lease settlement agreement (the "Termination Agreement") with the landlord, pursuant to which the lease term was reduced to expire on August 31, 2025. Under the Termination Agreement, the Company agreed to pay a one-time termination fee of $175,000 (plus applicable taxes) on or before November 30, 2025.

ABOUT AEQUUS PHARMACEUTICALS INC.

Aequus Pharmaceuticals Inc. (TSX-V: AQS) is a specialty pharmaceutical company, with a focus on commercializing value-added products in specialty therapeutic areas in the Canadian market.

FORWARD-LOOKING STATEMENT DISCLAIMER

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "potential" and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the penetration and growth of ZIMED® PF following its launch. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining regulatory approvals; general business and economic conditions; the Company's ability to successfully out license or sell its current product and in-license or develop new products; the assumption that the Company's current good relationships with third parties will be maintained; the availability of financing on reasonable terms; the Company's ability to attract and retain skilled staff; market competition; the products and technology offered by the Company's competitors; the impact of global events on the Company's operations; and the Company's ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading "Risk Factors" in the Management Discussion and Analysis, a copy of which is available on Aequus' profile on SEDAR+ at www.sedarplus.ca and as otherwise disclosed from time to time on Aequus' SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT INFORMATION

Aequus Investor Relations
Email: investors@aequuspharma.ca   Phone: 604-336-7906